Clinical Trials
7 trialsNCT06500273 2026-06-02
ALPHA3
Allogene Therapeutics
Phase 2 Recruiting
NCT06358430 2026-05-20
Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05735717 2026-04-06
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Masonic Cancer Center, University of Minnesota
Phase 2 Recruiting
NCT04991103 2025-12-31
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
University of Alabama at Birmingham
Phase 2 Recruiting
NCT01898039 2025-10-02
Modified Vaccine for High Risk or Low Residual Melanoma Patients
Hadassah Medical Organization
Phase 1/2 Recruiting
NCT05959720 2025-05-07
BRALLA
Instituto do Cancer do Estado de São Paulo
Recruiting
NCT02724163 2021-10-08
Myechild01
University of Birmingham
Phase 3 Recruiting